Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Faleck

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
The American Journal of Gastroenterology|May 22, 2023
IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center ExperienceAnusha Shirwaikar Thomas, Seung Eun Lee, Malek Shatila, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse EventsJia Luo, Jason A Beattie, Paige Fuentes, et al.
Inflammatory Bowel Diseases|January 4, 2019
Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative ColitisMatthew C Choy, Dean Seah, David M Faleck, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 20, 2024
Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE RegistrySteven H Itzkowitz, Yue Jiang, Cristina Villagra, et al.
Journal for Immunotherapy of Cancer|June 22, 2023
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitisYousef R Badran, Fangwen Zou, Sienna M Durbin, et al.
The Journal of Experimental Medicine|December 12, 2024
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitisJoan Shang, Diane Marie Del Valle, Graham J Britton, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2023
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitisPooja Middha, Rohit Thummalapalli, Michael J Betti, et al.
Nature Communications|March 27, 2024
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitisPooja Middha, Rohit Thummalapalli, Michael J Betti, et al.
Nature Communications|January 7, 2023
Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancersWalid K Chatila, Henry Walch, Jaclyn F Hechtman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2019
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel DiseaseHamzah Abu-Sbeih, David M Faleck, Biagio Ricciuti, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
The American Journal of Gastroenterology|May 22, 2023
IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center ExperienceAnusha Shirwaikar Thomas, Seung Eun Lee, Malek Shatila, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse EventsJia Luo, Jason A Beattie, Paige Fuentes, et al.
Inflammatory Bowel Diseases|January 4, 2019
Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative ColitisMatthew C Choy, Dean Seah, David M Faleck, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 20, 2024
Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE RegistrySteven H Itzkowitz, Yue Jiang, Cristina Villagra, et al.
Journal for Immunotherapy of Cancer|June 22, 2023
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitisYousef R Badran, Fangwen Zou, Sienna M Durbin, et al.
The Journal of Experimental Medicine|December 12, 2024
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitisJoan Shang, Diane Marie Del Valle, Graham J Britton, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2023
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitisPooja Middha, Rohit Thummalapalli, Michael J Betti, et al.
Nature Communications|March 27, 2024
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitisPooja Middha, Rohit Thummalapalli, Michael J Betti, et al.
Nature Communications|January 7, 2023
Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancersWalid K Chatila, Henry Walch, Jaclyn F Hechtman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2019
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel DiseaseHamzah Abu-Sbeih, David M Faleck, Biagio Ricciuti, et al.
Pageof 4